Improvement in left ventricular ejection fraction after pharmacological up-titration in new-onset heart failure with reduced ejection fraction.

Guideline adherence Heart failure Heart failure with reduced ejection fraction Multidisciplinary care Target doses

Journal

Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation
ISSN: 1568-5888
Titre abrégé: Neth Heart J
Pays: Netherlands
ID NLM: 101095458

Informations de publication

Date de publication:
Jul 2021
Historique:
accepted: 27 05 2021
pubmed: 15 6 2021
medline: 15 6 2021
entrez: 14 6 2021
Statut: ppublish

Résumé

Recent studies have reported suboptimal up-titration of heart failure (HF) therapies in patients with heart failure and a reduced ejection fraction (HFrEF). Here, we report on the achieved doses after nurse-led up-titration, reasons for not achieving the target dose, subsequent changes in left ventricular ejection fraction (LVEF), and mortality. From 2012 to 2018, 378 HFrEF patients with a recent (< 3 months) diagnosis of HF were referred to a specialised HF-nurse led clinic for protocolised up-titration of guideline-directed medical therapy (GDMT). The achieved doses of GDMT at 9 months were recorded, as well as reasons for not achieving the optimal dose in all patients. Echocardiography was performed at baseline and after up-titration in 278 patients. Of 345 HFrEF patients with a follow-up visit after 9 months, 69% reached ≥ 50% of the recommended dose of renin-angiotensin-system (RAS) inhibitors, 73% reached ≥ 50% of the recommended dose of beta-blockers and 77% reached ≥ 50% of the recommended dose of mineralocorticoid receptor antagonists. The main reasons for not reaching the target dose were hypotension (RAS inhibitors and beta-blockers), bradycardia (beta-blockers) and renal dysfunction (RAS inhibitors). During a median follow-up of 9 months, mean LVEF increased from 27.6% at baseline to 38.8% at follow-up. Each 5% increase in LVEF was associated with an adjusted hazard ratio of 0.84 (0.75-0.94, p = 0.002) for mortality and 0.85 (0.78-0.94, p = 0.001) for the combined endpoint of mortality and/or HF hospitalisation after a mean follow-up of 3.3 years. This study shows that protocolised up-titration in a nurse-led HF clinic leads to high doses of GDMT and improvement of LVEF in patients with new-onset HFrEF.

Identifiants

pubmed: 34125353
doi: 10.1007/s12471-021-01591-6
pii: 10.1007/s12471-021-01591-6
pmc: PMC8271074
doi:

Types de publication

Journal Article

Langues

eng

Pagination

383-393

Informations de copyright

© 2021. The Author(s).

Références

J Am Coll Cardiol. 2004 Apr 21;43(8):1423-9
pubmed: 15093878
J Am Heart Assoc. 2019 May 21;8(10):e011737
pubmed: 31094284
JACC Heart Fail. 2019 Apr;7(4):306-317
pubmed: 30852236
J Am Coll Cardiol. 2017 Nov 14;70(20):2476-2486
pubmed: 29141781
Eur J Heart Fail. 2016 Aug;18(8):891-975
pubmed: 27207191
Eur J Heart Fail. 2015 Apr;17(4):442-52
pubmed: 25727879
Cochrane Database Syst Rev. 2016 Mar 10;3:CD007451
pubmed: 26961574
J Am Coll Cardiol. 2019 May 21;73(19):2365-2383
pubmed: 30844480
Eur J Heart Fail. 2019 Mar;21(3):286-296
pubmed: 30537163
Arch Intern Med. 2008 Feb 11;168(3):316-24
pubmed: 18268174
Eur Heart J. 2017 Jun 21;38(24):1883-1890
pubmed: 28329163
Eur Heart J. 2012 Jul;33(14):1787-847
pubmed: 22611136
JACC Heart Fail. 2019 Sep;7(9):782-794
pubmed: 31401101
Heart. 2007 Jul;93(7):819-25
pubmed: 17065182
JACC Heart Fail. 2019 Nov;7(11):970-979
pubmed: 31606364
J Am Coll Cardiol. 2018 Aug 7;72(6):591-601
pubmed: 30071987
Int J Cardiovasc Imaging. 2013 Mar;29(3):581-8
pubmed: 22965859
JACC Heart Fail. 2019 Jan;7(1):13-21
pubmed: 30606482
JACC Heart Fail. 2018 Sep;6(9):725-733
pubmed: 30098965
Eur Heart J. 2017 Aug 7;38(30):2340-2348
pubmed: 28531281

Auteurs

J F Nauta (JF)

Department of Cardiology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.

B T Santema (BT)

Department of Cardiology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.

M H L van der Wal (MHL)

Department of Cardiology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.

A Koops (A)

Department of Cardiology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.

J Warink-Riemersma (J)

Department of Cardiology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.

K van Dijk (K)

Department of Cardiology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.

F Inkelaar (F)

Department of Cardiology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.

S Prückl (S)

Department of Cardiology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.

J Suwijn (J)

Department of Cardiology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.

V M van Deursen (VM)

Department of Cardiology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.

W C Meijers (WC)

Department of Cardiology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.

J Coster (J)

Department of Cardiology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.

B D Westenbrink (BD)

Department of Cardiology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.

R A de Boer (RA)

Department of Cardiology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.

Y Hummel (Y)

Department of Cardiology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.

J van Melle (J)

Department of Cardiology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.

D J van Veldhuisen (DJ)

Department of Cardiology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.

P van der Meer (P)

Department of Cardiology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.

A A Voors (AA)

Department of Cardiology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands. a.a.voors@umcg.nl.

Classifications MeSH